Abstract To provide data regarding clinical presentation, pathological features, management, and response to different treatments of patients with type I gastric neuroendocrine tumors in stages 0-2A. The study design consist of an Italian multicentre, retrospective analysis of patients with type I gastric neuroendocrine tumors managed with different therapeutic approaches: surgery, endoscopic surveillance, endoscopic resection, or somatostatin analog therapy. Among the 97 patients included, 3 underwent surgery, 45 (46.4 %) radical endoscopic resection of the neoplastic lesions, 13 (13.4 %) follow-up with upper endoscopy, and 36 (37.1 %) somatostatin analog therapy. At the end of the follow-up, all patients were alive and there was no evidence of metastatic disease. Somatostatin analog therapy resulted in a complete response in 76.0 % of the patients and stable disease in 24.0 %. A prolonged period of therapy, the use of a full dose of somatostatin analogs and higher gastrin levels at diagnosis were related to a complete response to the therapy. The recurrence rate was 26.3 % in patients treated with somatostatin analog therapy and 26.2 % in patients treated with endoscopic resection, without a statistically significant difference in terms of disease-free survival. Regarding recurrence of the disease, no statistical difference was found according to type of therapy, number of neoplastic lesions, and 2010 WHO classification. The only risk factor for tumor recurrence was a short period of medical treatment. In conclusion, our study suggested that endoscopic surveillance, endoscopic resection and somatostatin analog therapy represent valid options in the management of patients with type I gastric neuroendocrine tumors in stages 0-2A.
Gastric neuroendocrine neoplasms (gNENs-also called ''carcinoids'') are tumors derived from enterochromaffinlike cells (ECL-cells) localized in the gastric mucosa [1] . Three subtypes of ECL-cell tumors have been recognized [2] : type I lesions (70-80 %) are associated with chronic atrophic gastritis (CAG) and hypergastrinemia; type II lesions (5-8 %) are associated with gastrinomas in Zollinger-Ellison syndrome (ZES) and multiple endocrine neoplasia type I (MEN 1), and type III (15-20 %) are sporadic lesions arising in otherwise normal gastric mucosa without hypergastrinemia [2] .
Neoplastic changes in ECL-cells (types I and II gNENs) are always associated with an elevated concentration of circulating serum gastrin [2] , which exerts a trophic effect on ECL-cells, leading to hyperplasia and, in some cases, to a true neuroendocrine neoplasm [3, 4] . The majority of type I gNENs occur in women and are rarely symptomatic [5] . They are non-functioning tumors, typically found during upper gastrointestinal (GI) endoscopy for dyspepsia or anemia [6] . Type I gNENs frequently present as multiple polyps, usually \1 cm in diameter, localized in the gastric corpus-fundus. They are almost exclusively benign lesions with a low risk of deep invasion of the gastric wall [7] . These tumors have a good prognosis with the 5-year survival rate quoted at 96 % which does not differ from an age-matched normal population [5, 8] .
Therapeutic strategies for type I gNENs (ranging from endoscopic surveillance to surgery) are based on risk stratification according to tumor size, lesion number, stage, and grade [5, 9, 10] . Current European Neuroendocrine Tumor Society (ENETS) guidelines for the management of patients with type I gNENs suggest endoscopic management with lesion resection [11] , while a surgical approach should be limited to cases of clearly demonstrated invasion beyond the submucosa and/or with metastases. The current literature points out the elevated variability which exists between treatments in cases of multiple, localized (mucosa or submucosa) type I gNENs: (1) careful endoscopic follow-up without any treatment [12] [13] [14] , (2) somatostatin analog (SSA) therapy [9, 15, 16] and (3) endoscopic resection [10, 17] . Two papers have recently been published in which a retrospective analysis of patients with type I gNENs treated with different approaches was carried out. Thomas et al. compared endoscopic resection with surgical treatment [18] , while Sato et al. compared endoscopic surveillance with endoscopic resection [19] .
The aim of this retrospective study was to provide data regarding the clinical presentation, pathological features, management, and response to different treatment modalities in a large cohort of patients with type I gNENs.
Patients and methods

Study design and patients
The study design consisted of an Italian multicentre, retrospective analysis. The study included all consecutive patients with type I gNENs followed at the participating centers (i.e., Bologna, Milan-IEO, Perugia, Naples, Udine, Genova) from June 1998 to December 2013.
Demographic data, as well as clinical and pathological features, were collected in a dedicated computerized database including: (1) baseline situations with demographic data, past medical history, symptoms at diagnosis of the gNEN, evaluations of parietal cell antibodies (PCA), serum gastrin levels and plasma/serum levels of Chromogranin A (CgA), findings at endoscopy and endoscopic ultrasound (EUS), and the pathological features of gNENs and CAG; (2) type of therapy (surgery, endoscopic resection, SSAs, endoscopic surveillance) and (3) follow-up data and status at last visit.
Data analysis
A dedicated computerized database was created, and demographic data, as well as pathological features, were retrospectively analyzed. The histological specimens were examined by an expert NEN-dedicated pathologist at each centre. When required, additional centralized revision of the tumor specimens was carried out. The degree of atrophy of the gastric mucosa was classified according to the updated Sydney system classification [20] .
The tumors were classified according to the 2010 WHO classification [21] and the tumor node metastasis (TNM) classification/G grading system [22] . The Ki67 proliferation index was expressed as a percentage based on the number of Ki67-positive cells in 2000 tumor cells in the areas of the highest immunostaining using the MIB1 antibody (DBA, Milan, Italy).
The response to therapy was classified as: complete response (CR): the disappearance of all signs (endoscopic and histologic) of gNEN; progressive disease (PD): stage increase of gNEN and stable disease (SD): no change in terms of gNEN stage. Disease-free survival (DFS) was defined as the interval between the endoscopic and pathologic evidence of being disease free and the time of disease recurrence (DR). Disease-free survival was measured using the Kaplan-Meier method, and the results were compared using the log-rank test. Analysis of the predictive risk factors for DR was carried out by univariate analysis using the Cox proportional hazards method. Risk factors were expressed as hazard ratios (HRs) [95 % confidence interval (CI)]. All analyses carried out for risk factors are listed in tables. The distribution of the continuous variables was reported as median and interquartile ranges (IQRs, 25th to 75th percentiles). Comparison between the subgroups was carried out using Pearson's Chi-square test (Fisher's exact test was used when necessary) or the Mann-Whitney U test for continuous variables. The p value was considered significant when \0.05. The statistical analysis was carried out using dedicated software (IBM-SPSS Statistics version 19.0).
Results
Study population
Ninety-seven patients with gNENs associated with CAG were enrolled at the participating centers. The characteristics of all 97 patients are listed in Table 1 . There were 38 males and 59 females with a median age of 59.0 years (IQR 49.0-66.0 years). In 24 patients (24.7 %), the diagnosis of gNEN was incidental, in 48 (49.5 %) as a result of dyspepsia and in 25 (25.8 %) as a result of anemia. Seventy-three (75.3 %) patients had autoimmune disease with positive PCA and 19 (19.6 %) with negative PCA (not evaluated in 5 patients). All patients had serum gastrin levels above the normal value (median: 964.0 pg/ml; IQR: 585.0-1702.0 pg/ml). The median CgA level, evaluated in 54 patients using enzyme-linked immunosorbent assay (ELISA), was 77.5 U/l (IQR: 41.0-198.0 U/l). In 25 patients, CgA evaluation was carried out using radioimmunoassay (RIA) (median: 216.0 pg/ml; IQR: 110.0-353.0 pg/ml). Therefore, CgA was not evaluated in 18 patients.
At upper gastrointestinal endoscopy, 60 patients (61.9 %) were found to have fewer than 5 polyps in the body-fundus and 37 (38.1 %) to have more than 5 lesions; the median lesion diameter was 5 mm (IQR 3-10 mm). Atrophy of the gastric mucosa was mild in 18 patients (18.6 %), moderate in 32 (33.0 %), and severe in 36 (37.1 %) an CAG without grade of atrophy was described in 11 patients (11.3 %). No patient had Helicobacter Pylori infection. According to the 2010 WHO classification, 56 patients (57.8 %) had a NET G1, 33 (34.0 %) a NET G2 and, in 8 patients, histological examination was not possible due to the scarcity of the tissue samples. The median Ki67 index was 2.0 % (IQR 1.0-3.0 %). At diagnosis, 84 patients (86.6 %) were in stages 0-1, 8 (8.2 %) in stage 2A (lesions limited to the submucosa but having a diameter between 1 and 2 cm) and 3 (3.1 %) in stage 3B (median lesion diameter: 30 mm, range 25-35 mm; 1 NET G1 and 2 NET G2; 2 T2N1 and 1 T3N1). Therefore, the stage of the disease was not evaluated in 2 patients.
Tumor treatment
The tumor treatment of the 97 patients is listed in Table 1 ; 45 (46.4 %) patients underwent radical endoscopic resection of the neoplastic lesions, 13 (13.4 %) were followed up by endoscopy, 36 (37.1 %) received SSA therapy with or without partial endoscopic resection [20 (20.6 %) patients were treated with SSAs only and 16 (16.5 %) with both partial endoscopic resection and SSAs]. In 3/97 (3.1 %) patients with stage 3B, radical surgery was carried out. As reported in Table 1 , endoscopic resection was preferred in patients having fewer than 5 lesions (p \ 0.001); SSA therapy was preferred in patients with NET G1s (p = 0.013) who had lower Ki67 (p = 0.017) and higher gastrin levels (p = 0.005).
The median follow-up was 30.5 months (IQR: 12.0-64.2 months). Sixty-four patients were disease free at follow-up (31 after endoscopic resection, 4 after a simple follow-up, 26 after somatostatin analog therapy and 3 after radical surgery); 14 had stable disease (9 after a simple follow-up, 5 after SSA therapy); 16 had a recurrence of the disease (11 after complete endoscopic resection and 5 after SSA therapy) and 3 were lost to follow-up. At the end of the follow-up period, all patients were alive and none presented metastatic disease (lymph node or liver).
In order to undergo SSA therapy, 9/36 patients gave their informed written consent, and the therapy was approved by the local Ethics Committee [9] . The remaining 27 patients were treated according to ''extension of indication for uses (of somatostatin analogs) consolidated on the basis of scientific evidence in the literature.''
The flowchart of patients therapy is shown in Fig. 1 .
Endoscopic surveillance
Thirteen (6 males and 7 females, median age: 62 years, IQR: 50-65 years) patients were followed up, without any additional treatment, for a median period of 82.0 months (IQR: 34.0-120.0 months). In 2 patients, there were fewer than 5 lesions while, in 11 patients, there were more than 5 neoplastic lesions. The median lesion diameter was 4.5 mm (IQR: 3.0-10.0). Three patients had a NET G1 while 8/13 had a NET G2; the median Ki67 level was 3 % (IQR: 2.0-5.0). During follow-up, there was complete disappearance of the neoplastic lesions in 4 patients (30.8 %); in the remaining 9 cases, there was stable disease in terms of stage of the disease (8 stage I and 1 stage IIA).
Endoscopic resection
Forty-five (14 males and 31 females, median age: 61 years, IQR: 49-71 years) patients were treated with endoscopic resection (polypectomy, endoscopic mucosal dissection, endoscopic submucosal dissection). In 41 patients, there were fewer than 5 lesions while, in 4 patients, there were more than 5 neoplastic lesions. The median lesion diameter was 5.0 mm (IQR: 3.0-8.0). Twenty-eight patients had a NET G1 while 16 had a NET G2; the median Ki67 level was 
Somatostatin analog therapy
Thirty-six patients (37.1 %) were treated with long-acting SSAs. In 11/36 (30.5 %) patients, there was no evidence of residual disease after endoscopy (complete endoscopic resection) while, in 25/36 (69.5 %), there was evidence of residual disease (the presence of at least one neoplastic lesion histologically proven and not removed). The characteristics of these 25 patients are listed in Table 2 . Nineteen patients (76 %) had a complete response after a median period of The gastrin serum levels at diagnosis were significantly higher in patients with a complete response (1882.0 vs. 954.0 pg/ml; p = 0.039). No differences were found between complete response and stable disease regarding sex, the presence of PCA, the number of gastric polyps, the grade of atrophy, 2010 WHO classification, the stage of the disease, the associated partial endoscopic resection, Ki67 % and lesion diameter. Of the 11 patients without evidence of residual disease after endoscopy who were treated with SSAs, 5/11 were being treated with SSAs at the moment of the study (median length of therapy: 36 months; IQR 31-60) without DR, 5/11 were not being treated with SSR therapy and had DR (median length of therapy: 14 months, IQR 13-21; median follow-up: 34 months; IQR 30-49) and one patient had DR after 69 months of therapy.
Predictors of tumor recurrence and disease-free survival
Of the 64 patients having a complete response after therapy, 3 were lost to follow-up; 42/61 (68. The variables considered as risk factors for tumor recurrence after medical or endoscopic treatment are summarized in Table 3 . The only risk factor for tumor recurrence was a short period of medical treatment (HR 0.38, p = 0.024). In particular, no recurrence was found in patients when the period of medical treatment was 17 months or longer (Fig. 3-median 
Discussion
Therapeutic strategies for type I gNENs, ranging from endoscopic surveillance to surgery, are based on risk stratification according to tumor size, number of neoplastic lesions, stage, and grade [5, 9, 10] . The current ENETS guidelines for the management of patients with type I gNENs suggest endoscopic management with lesion resection [11] while a surgical approach should be limited to cases of invasion beyond the submucosa and/or with nodal involvement.
In this multicentre retrospective study, the outcome of three main therapeutic approaches were analyzed in 94 patients with type I gNENs: endoscopic resection (46.4 %), endoscopic surveillance (13.4 %), and SSA therapy (37.1 %).
The study showed that, in patients with stages 0-2A type I gNENs, endoscopic surveillance, endoscopic resection, or SSA therapy were all feasible and potentially effective; no nodal or distant metastases occurred and there was 100 % survival at the end of the follow-up. The use of SSA therapy in type I gNENs is still under debate. In the literature, there are prospective studies involving small numbers of patients which have reported the efficacy of SSA therapy in a specific setting of patients with type 1 gNENs [9, 15] . Given the absence of prospective randomized trials, according to the ENETS guidelines, the use of SSAs is still under debate and should be proposed only in accordance with expert opinion.
According to the literature, SSA therapy produced a CR of 76.0 % and SD of 24.0 % with no cases of progression [9, 15, 23, 24] . These data underscore the potential role of these drugs in this setting due to their antiproliferative effect and the reduction of gastrin levels [9, 25] . Our data suggest the importance of using a full dose of SSAs (Lanreotide Autogel 120 mg or Octreotide LAR 30 mg every 28 days) and a prolonged period of therapy in order to obtain a complete response. To our knowledge, no data regarding these aspects have previously been reported.
An additional finding provided by this study was a relatively low recurrence rate. In particular a disease recurrence of 26.3 % occurred in patients treated with SSAs and 26.2 % in patients treated with endoscopic resection without a statistically significant difference in terms of disease-free survival (median: 117 months). Another observation in our study not previously reported in the literature was that there was the same risk of disease recurrence using SSAs and endoscopic resection.
Regarding the recurrence rate after endoscopic resection, our data showed a lower percentage as compared with those of Merola et al. who reported a 63.6 % recurrence rate after endoscopic resection using a forceps (54.4 %) or by snare (45.5 %) with a recurrence-free survival of Studying predictors of disease recurrence shows that only prolonged medical therapy has a positive prognostic role. In particular, medical treatment for 17 months or longer seemed to prevent the risk of recurrence with a median follow-up of up to 62 months. Our data are the first to suggest a minimal period for therapy in patients treated with SSAs.
A possible limitation of SSA therapy or endoscopic submucosal dissection is the high cost of these therapeutic options. Only a specific cost/effectiveness study can evaluate this aspect.
In our retrospective analysis, endoscopic surveillance, carried out in 13/94 patients, seemed to be a reasonable alternative to medical or endoscopic therapy. In fact, stable disease or disappearance of the disease (4 cases) was not observed after a median follow-up of 82.0 months. This evidence confirmed the data in the literature which indicated the potential role of endoscopic surveillance in selected patients with type I gNENs [14] .
It is noteworthy that, in our study, all the patients treated with a conservative strategy (endoscopic surveillance, endoscopic resection or SSA therapy) had stage 0 or stage I lesions. Patients with stage 2A lesions had tumor lesions limited to the submucosa having a diameter between 1 and 2 cm. The 2 cases with T2 lesions, having a diameter greater than 2 cm, had lymph node involvement at endoscopic ultrasound (stage 3B). Regarding this aspect, La Rosa et al. described the statistically significant increased risk of tumor metastases in patients with invasion of the deep submucosa, also with the presence of a lesion diameter between 1 and 3 cm [26] . As a result of these data, in our opinion, it is useful to carry out an endoscopic ultrasound evaluation in all patients with a lesion diameter [1 cm or with a lesion diameter \1 cm but with deep submucosal invasion (shown histologically) in order establish the neoplastic extension into the gastric wall and the perigastric lymph node status prior to establishing the therapeutic approach.
The possible limitations of our study include different time intervals of endoscopic follow-up, the lack of a centralized revision of the pathological specimens and a heterogeneous thefrapeutic approach (type of endoscopic resection, and type and duration of SSA therapy). Despite this aspect, our retrospective study reports some interesting data and presents many ideas for future prospective studies.
In conclusion, our study suggests that endoscopic surveillance, endoscopic resection, and SSA therapy are all valid options in the management of patients with type I gNENs in stages 0-2A. The risk of recurrence is the same in patients treated with endoscopic resection and SSA therapy. In patients treated with SSAs, at least 17 months of medical therapy is recommended in order to increase the possibility of obtaining a complete response and of reducing the risk of disease recurrence.
Although type I gNENs are quite rare, prospective randomized trials to compare the different therapeutic options and to evaluate the cost of these options are warranted.
